GSK's RSV vaccine is poised for EU approval in all adults aged 18 and over, bringing it into line with rival shots from Pfizer and Moderna.

Emma Walmsley and her GSK CEO successor, Luke Miels, are safeguarding the British pharma’s 40 billion-pound-sterling sales projection for 2031 on the back of a strong quarter. | Emma Walmsley and her ...

YouTube video by Those Nerdy Girls

Read the full article on Monterey County Now.

Almost all children get RSV at least once before they are 2 years old. For most healthy children, RSV is like a cold. But some children get very sick with RSV. Learn the symptoms and how to protect yo...

A single dose of the RSV vaccine offers 58% protection against hospitalization in older adults, but effectiveness varies in immunocompromised individuals.

One shot of an RSV vaccine protects adults ages 60 or older from RSV-associated hospitalization and critical illness during two consecutive RSV seasons. ...

🔬💉 Vaccine Breakthroughs: mRNA Settlements, Cancer Vaccine Trials, RSV Effectiveness & More   This week’s Vaccine Research roundup brings you […] The post Vaccines Weekly Update – August 14th 2025 appeared first on LucidQuest Ventures.

🔬💉 Vaccine Breakthroughs: mRNA Settlements, Cancer Vaccine Trials, RSV Effectiveness & More   This week’s Vaccine Research roundup brings you […] The post Vaccines Weekly Update – August 14th 2025 appeared first on LucidQuest Ventures.

🔬💉 Vaccine Breakthroughs: mRNA Settlements, Cancer Vaccine Trials, RSV Effectiveness & More   This week’s Vaccine Research roundup brings you […] The post Vaccines Weekly Update – August 14th 2025 appeared first on LucidQuest Ventures.

The dominoes have stalled, which can turn out to be a big problem.

🔬💉 Vaccines Global Breakthroughs: Clinical Updates From India to the EU and More 🌍💉🧬 In this week’s edition of Vaccine […] The post Vaccines Weekly Update – July 18th 2025 appeared first on LucidQuest Ventures.

🔬💉 Vaccines Global Breakthroughs: Clinical Updates From India to the EU and More 🌍💉🧬 In this week’s edition of Vaccine […] The post Vaccines Weekly Update – July 18th 2025 appeared first on LucidQuest Ventures.

🔬💉 Vaccines Global Breakthroughs: Clinical Updates From India to the EU and More 🌍💉🧬 In this week’s edition of Vaccine […] The post Vaccines Weekly Update – July 18th 2025 appeared first on LucidQuest Ventures.

(Reuters) -British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the use of its respiratory syncytial virus (RSV) vaccine to adults under the age of 50 at a higher risk of the disease. If approved in the world’s biggest pharmaceuticals market, GSK’s vaccine, Arexvy, would be competing for a market share in the 18-49 age group with Moderna (NASDAQ:MRNA)’s mRESVIA and Pfizer (NYSE:PFE)’s Abrysvo. RSV is a common respiratory virus that causes seasonal infections such as the flu and is a leading cause of pneumonia and death in infants and older adults. GSK’s vaccine is currently approved in the U.S. for preventing RSV-related disease in adults aged 60 and above, and in at-risk adults aged 50 to 59. While it had a lead in approvals initially, it has since lagged behind rivals and sales have fallen sharply. The FDA is expected to make a decision on the expanded use of Arexvy in the first half of 2026, GSK said. European regulators are also expected to rule on a similar application by then. With GSK making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed GSK alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including GSK, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is GSK poised for similar growth? Don't miss the opportunity to find out.

Investing.com -- British drugmaker GSK (NYSE:GSK) has submitted an application to the U.S. Food and Drug Administration (FDA) to extend the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, to adults under the age of 50 who are at higher risk of the disease. The company announced the submission on Monday. Arexvy is currently approved for older adults, and this application aims to make the vaccine available to a younger population with elevated risk factors for RSV. RSV is a common respiratory virus that can cause serious illness, particularly in vulnerable populations. The application represents GSK’s effort to broaden protection against RSV to additional at-risk groups. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. ProPicks AI are 6 model portfolios created by Investing.com which identify the best stocks for investors to buy now. The stocks that made the cut could produce monster returns in the coming years. Is GSK one of them?

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

The U.S. Centers for Disease Control and Prevention in a report on Thursday said that hospitalizations related to RSV decreased by 28% and 43% across two large national databases, compared to pooled rates from 2018-2020. The 2024-2025 season marked the first period of widespread availability of preventive shots against RSV, a virus that often results in cold-like symptoms but is a major cause of severe infection and death in infants and older adults.

ISPOR, subscriptions, RSV vaccine explained! Healthcare's future, decoded for you. Beginner's guide.

Far fewer babies went to the hospital struggling to breathe from RSV, a severe respiratory infection, after the debut of a new vaccine and treatment this season, according to an analysis published today...

Saskatchewan is expanding its infant RSV immunization program to include all babies born one month before and during RSV season, which typically lasts from the start of October until the end of March.

By Blake Brittain (Reuters) -British pharmaceutical giant GlaxoSmithKline (NYSE:GSK) and rival Pfizer (NYSE:PFE) have agreed to end a lawsuit that alleged Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK’s patent rights in its competing RSV shot Arexvy, according to a Thursday filing in Delaware federal court. GSK and Pfizer said in the filing that they would dismiss the case with prejudice, which means it cannot be refiled. Spokespeople for the companies did not immediately respond to requests for comment and more information, including whether the case was settled. GSK, Pfizer and Moderna (NASDAQ:MRNA) have developed RSV shots approved by the U.S. Food and Drug Administration, with GSK’s Arexvy responsible for the majority of U.S. RSV vaccine sales. The respiratory disease typically causes cold-like symptoms, but it is also a leading cause of pneumonia in toddlers and older adults. GSK sued Pfizer in 2023, arguing that the New York-based company’s vaccine infringed GSK patents related to antigen technology. GSK said in the lawsuit that Pfizer began working on its RSV program around 2013, at least seven years after GSK began developing its shot. GSK has also sued Pfizer for patent infringement in the U.S. over technology in Pfizer’s blockbuster COVID-19 vaccine Comirnaty. That case is still ongoing.